EXCLUSIVE: US House committee opens investigation into Merck, AbbVie China drug trials
A US House committee has launched an investigation into drug trials conducted in China by pharmaceutical giants Merck and AbbVie. The probe appears to center on the companies' clinical research activities in China and the oversight surrounding them.
Why this matters: When drug trials happen in China, American patients are often downstream of the results without knowing it. If a treatment gets approved based on that data, the quality and integrity of that data matters to anyone who eventually takes the drug. Congressional scrutiny of Merck and AbbVie suggests there are real concerns about oversight, not just geopolitical optics. The core issue is accountability: who vouches for the data, and what happens if the trials did not meet the standards patients assume they did.
Who should care: Lawyers · Privacy officers · Compliance
This summary is AI-assisted and may contain errors. It is an original briefing to help you gauge significance quickly — not a reproduction of the source. Always read the linked original before relying on it. See our methodology.